Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Kwak, Lucia"'
Autor:
Sperger JM; Department of Medicine, Carbone Cancer Center, University of Wisconsin, Madison, WI., Emamekhoo H; Department of Medicine, Carbone Cancer Center, University of Wisconsin, Madison, WI., McKay RR; Moores Cancer Center, University of California San Diego, La Jolla, CA., Stahlfeld CN; Department of Medicine, Carbone Cancer Center, University of Wisconsin, Madison, WI., Singh A; Department of Medicine, Carbone Cancer Center, University of Wisconsin, Madison, WI., Chen XE; Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada., Kwak L; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Gilsdorf CS; Department of Medicine, Carbone Cancer Center, University of Wisconsin, Madison, WI., Wolfe SK; Department of Medicine, Carbone Cancer Center, University of Wisconsin, Madison, WI., Wei XX; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Silver R; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Zhang Z; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Morris MJ; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY., Bubley G; Beth Israel Deaconess Medical Center, Boston, MA., Feng FY; Division of Hematology and Oncology, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA.; Department of Radiation Oncology, University of California San Francisco, San Francisco, CA.; Department of Urology, University of California San Francisco, San Francisco, CA., Scher HI; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY., Rathkopf D; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY., Dehm SM; Departments of Laboratory Medicine and Pathology and Urology, Masonic Cancer Center, University of Minnesota, Minneapolis, MN., Choueiri TK; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Halabi S; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC.; Department of Biostatistics and Bioinformatics, Duke University, Durham, NC., Armstrong AJ; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC., Wyatt AW; Department of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada., Taplin ME; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Zhao SG; Department of Medicine, Carbone Cancer Center, University of Wisconsin, Madison, WI.; Department of Human Oncology, University of Wisconsin, Madison, WI.; William S. Middleton Memorial Veterans Hospital, Madison, WI., Lang JM; Department of Medicine, Carbone Cancer Center, University of Wisconsin, Madison, WI.; Department of Medicine, University of Wisconsin, Madison, WI.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Sep 10; Vol. 39 (26), pp. 2926-2937. Date of Electronic Publication: 2021 Jul 01.
Autor:
McKay RR; University of California San Diego, San Diego, California.; Dana-Farber Cancer Institute, Boston, Massachusetts., Kwak L; Dana-Farber Cancer Institute, Boston, Massachusetts., Crowdis JP; Dana-Farber Cancer Institute, Boston, Massachusetts., Sperger JM; Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin., Zhao SG; Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin., Xie W; Dana-Farber Cancer Institute, Boston, Massachusetts., Werner L; Dana-Farber Cancer Institute, Boston, Massachusetts., Lis RT; Dana-Farber Cancer Institute, Boston, Massachusetts., Zhang Z; Dana-Farber Cancer Institute, Boston, Massachusetts., Wei XX; Dana-Farber Cancer Institute, Boston, Massachusetts., Lang JM; Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin., Van Allen EM; Dana-Farber Cancer Institute, Boston, Massachusetts., Bhatt RS; Beth Israel Deaconess Medical Center, Boston, Massachusetts., Yu EY; University of Washington, Seattle, Washington.; Fred Hutchinson Cancer Research Center, Seattle, Washington., Nelson PS; University of Washington, Seattle, Washington.; Fred Hutchinson Cancer Research Center, Seattle, Washington., Bubley GJ; Beth Israel Deaconess Medical Center, Boston, Massachusetts., Montgomery RB; University of Washington, Seattle, Washington.; Fred Hutchinson Cancer Research Center, Seattle, Washington., Taplin ME; Dana-Farber Cancer Institute, Boston, Massachusetts. mtaplin@partners.org.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jul 01; Vol. 27 (13), pp. 3610-3619. Date of Electronic Publication: 2021 Apr 13.
Autor:
McKay, Rana R., Kwak, Lucia, Crowdis, Jett P., Sperger, Jamie M., Zhao, Shuang G., Xie, Wanling, Werner, Lillian, Lis, Rosina, Zhang, Zhenwei, Wei, Xiao X., Lang, Joshua M., Van Allen, Eliezer M., Bhatt, Rupal S., Yu, Evan Y., Nelson, Peter S., Bubley, Glenn J., Montgomery, R. Bruce, Taplin, Mary-Ellen
Publikováno v:
Clin Cancer Res
PURPOSE: Enzalutamide is a second-generation androgen receptor (AR) inhibitor which has improved overall survival (OS) in metastatic castration resistant prostate cancer (CRPC). However, nearly all patients develop resistance. We designed a phase 2 m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::267d08a3d5f37136c9df5055d2375f5d
https://europepmc.org/articles/PMC8254786/
https://europepmc.org/articles/PMC8254786/